Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod in Myasthenic Crisis
NCT06688253Phase 4Not yet recruiting
- Sponsor
- Rambam Health Care Campus
- Start
- Nov 2024
- Primary completion
- Jan 2025
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 4, open-label trial of efgartigimod alfa in myasthenia gravis (MG) (2 arms), sponsored by Rambam Health Care Campus. Primary endpoint: Myasthenia Gravis Activities of Daily Living Improvement at 1 month. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06688253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06688253.